Clinical Trial Update: Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial [Phase 2]

View source ↗

Summary

A Phase 2, controlled trial evaluated percutaneous delivery of a VEGF-A165/bFGF plasmid to promote angiogenesis in patients with no-option coronary artery disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• VEGF-A165/bFGF plasmid

Snippet

Sponsor: National Institute of Cardiology, Warsaw, Poland | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED